Skip to Content

Johnson & Johnson JNJ Stock Quote

| Rating as of


Market Open

| Currency in USD

  • Last Close 162.91
  • Sector Healthcare
  • Industry Drug Manufacturers - General
  • Investment Style Large Value
  • Day Range 161.73  –  163.50
  • Year Range 150.11  –  181.04
  • Market Cap 391.0213 Bil
  • Volume / Avg 1.7 Mil /  22.3 Mil
  • Price / Sales 4.41
  • Price / Book 5.63
  • Forward Div Yield 2.92%
  • Trailing Div Yield 2.86%

Morningstar‘s Stock Analysis JNJ

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Johnson & Johnson: Updated Guidance Following Kenvue Divestment Consistent With Our Expectations

Damien Conover Sector Director

Analyst Note

| Damien Conover |

Following the successful split-off of Johnson & Johnson’s consumer division, Kenvue, J&J provided updated 2023 guidance for the remaining J&J business largely in line with our expectations. We don’t expect any changes to the firm’s fair value estimate or wide moat rating based on the updated outlook. The 2023 earnings outlook for the remaining J&J business fell as expected due to the divested consumer business. However, the reduced share count from the Kenvue split-off combined with $13 billion in proceeds from the debt offering and partial initial public offering of Kenvue as well as the 9.5% remaining stake of Kenvue still held by J&J largely offset the lost Kenvue earnings from a valuation perspective.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics JNJ

Company Profile JNJ

Business Description

Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.

One Johnson and Johnson Plaza
New Brunswick, NJ, 08933
Industry Drug Manufacturers - General
Employees 155,800

Related Articles JNJ

Morningstar analysts hand-select direct competitors or comparable companies to provide context on the strength and durability of JNJ’s competitive advantage.

Johnson & Johnson


Eli Lilly and Co


Merck & Co Inc


Procter & Gamble Co

−$0.52 (0.32%) −$22.67 (3.98%) +$0.25 (0.23%) −$0.37 (0.24%)
Market Cap
391.02 Bil519.34 Bil272.91 Bil360.85 Bil
Drug Manufacturers - General Drug Manufacturers - General Drug Manufacturers - General Household & Personal Products
Consumer Defensive

* Trading data in this section is delayed by at least 15 minutes.

FAQs for Johnson & Johnson Stock

Yes. JNJ has a forward dividend yield of 2.92%. See JNJ’s full dividends and stock split history on the Dividend tab.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

JNJ’s market cap is 391.02 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

JNJ’s stock style is Large Value.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

JNJ’s price/sales is 4.41.
Price/sales represents the amount an investor is willing to pay for a dollar generated from a particular company’s sales or revenues.

JNJ’s price/forward earnings is 33.04.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. The lower the Forward P/E, the cheaper the stock.

JNJ’s price/book is 5.63.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets, based on historical, rather than current, valuations. Historical valuations generally do not reflect a company’s current market value. Value investors frequently look for companies that have low price/book ratios.

See JNJ’s valuation ratios compared to the Market Index.

JNJ’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare JNJ’s historical performance against its industry peers and the overall market.